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Abstract
To establish magnetic resonance imaging (MRI) features that differentiate residual tumors from postoperative surgical changes
following the transsphenoidal approach of a pituitary adenoma.
We analyzed residual enhancements at the tumor bed in 52 patients who underwent dynamic contrast-enhanced sella MRI within
48hours after surgery and at 6 to 28 months. Patients were divided into 2 groups deﬁned by either peripheral or nodular
enhancement patterns. For each group, we measured the maximum thickness of the residual enhancing portion and compared
differences in the residual tumor and postoperative changes.
Among the tumors examined in the 52 patients, 19 residual tumors showed nodular (n=16) and peripheral (n=3) enhancement
patterns, and 33 postoperative changes showed nodular (n=3) and peripheral (n=30) enhancement patterns. The mean residual
tumor thickness was 7.1mm (range, 2.9–16.8mm) and 1.9mm (range, 1.0–7.4mm) in the postoperative change. Receiver operating
characteristic curve analysis revealed that a 3.9-mm thickness was associated with 89% sensitivity, 97% speciﬁcity, and 94%
accuracy for diagnosis of residual tumor.
On immediate postoperative MRI, residual enhancement with greater than 3.9-mm thickness and nodular pattern suggest residual
pituitary adenoma tumor.
Abbreviations: DWI = diffusion-weighted imaging, MRI = magnetic resonance imaging, PWI = perfusion-weighted imaging.
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approach1. Introduction
Magnetic resonance imaging (MRI) is frequently used in the
postoperative follow-up of pituitary adenoma, particularly
nonfunctioning adenoma.[1–4] Most residual pituitary tumors
are in areas where surgery is difﬁcult, such as the cavernous sinus,Editor: Kai Wu.
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1the suprasellar cistern (in very ﬁrm tumors), or the posterior clivus.
However, not all residual tumors are located in these areas. Several
studies have reported that immediate postoperative MRI can
establish baseline postoperative status and immediately detect
postoperative complications.[2,3,5] The interpretation of postoper-
ative MR images of the sella turcica region is difﬁcult because the
postoperativeappearanceof the excision site dependsonnumerous
factors, such as the size and extent of the adenoma before surgery,
the surgical approach, the quality and amount of implanted
materials, and the time course of resorption of postoperative
changes.[1] The height of the pituitary mass might not return to
normal immediately after surgery because of blood clot accumu-
lation in the sella, packingmaterial suchasmuscle or fat in the sella,
or adhesion between the diaphragm sellae and overlying tumor or
brain tissue.[6] Early detection of residual tumors is an opportunity
for an immediate second operation, via the same transsphenoidal
approach, before adhesion develops at the operation site. A
previous study that analyzed early postoperative MRI following
transsphenoidal resection, attempted to differentiate residual
tumors from postoperative surgical changes. They found that all
patients with a residual tumor showed nodular or combined
nodular and peripheral enhancement.[7] However, this study,
which investigated the enhancement patterns of the postoperative
pituitarymass, was constrained by the lack of a sensitive, objective
method for detecting residual tumors.
The purpose of this study was to establish diagnostic features
of immediate postoperative MR imaging that differentiate
Kim et al. Medicine (2019) 98:27 Medicineresidual tumors from postoperative surgical changes after the
transsphenoidal resection of a pituitary adenoma.2. Materials and methods
2.1. Patients
A total of 52 patients with pituitary mass, showing suprasellar
extension on preoperative MRI and pathologically conﬁrmed
pituitary adenoma, were retrospectively reviewed from May
2012 to March 2015 at the Samsung Medical Center in Seoul,
South Korea. All patients underwent dynamic contrast-enhanced
sella MRI preoperatively, within 48hours after surgery, and
during the following 6 to 28 months. MR images with severe
artifacts affecting image interpretation were excluded. The
institutional review board of the hospital (Samsung Medical
Center) approved the study and the board waived the
requirement of informed consent because there are no human
beings or animals involved in this study.2.2. MR imaging
Magnetic resonance imaging was performed at 3-T (Achieva,
Philips Medical Systems Best, The Netherlands) using 8-channel
head coils. Conventional T1-weighted and T2-weighted imaging,
conventional contrast-enhanced T1-weighted imaging, and
dynamic contrast-enhanced MR imaging were performed. The
coronal plane was acquired for each image and the sagittal plane
was acquired for unenhanced conventional T1-weighted images.
Unenhanced and contrast-enhanced T1-weighted images were
obtained using spin echo sequence with repetition time (TR)/echo
time (TE)/number of excitations (NEX)=500/10/1; matrix=
256205; section thickness=2mm, slice gap=2mm, ﬂip angle
(FA)=70°; ﬁeld of view (FOV)=180180mm; and imaging
time=4minutes.
Dynamic contrast-enhanced MR images were obtained after a
single bolus injection of gadolinium-based MR contrast medium
(gadoterate meglumine, Dotarem, Gurebet, Aulnay-sous-Bois,
France; or gadobutrol, Gadovist, Bayer Schering Pharma,
Berling, Germany) (0.1mmol/kg body weight; injection rate=
1ml/s) followed by a saline ﬂush of 20ml. We used a turbo spin
echo sequence with TR/TE/NEX=400–824/8.6–13/1; echo train
length=4; parallel image technique; SENSE factor=2; matrix=
400177; reconstruction matrix=704; section thickness=2.5–
3.0mm; no slice gap; FA=90°; FOV=180–210180–210mm.2.3. Imaging analysis
Two neuroradiologists (S.T.K, a board-certiﬁed neuroradiologist
with 18 years of experience and H.Y.K, a board-certiﬁed
fellowship-trained radiologist) retrospectively and independently
analyzed the MR images. Reviewers were blinded to patient
identities and pathological and clinical data. The size of each
initial pituitary mass using the largest (oblique) diameter on any
coronal or sagittal image wasmeasured.Wemeasured the sizes of
pituitary masses and identiﬁed displaced normal glands in
preoperative MR images. Normal gland locations were demon-
strated against the pituitary adenoma according to degree of
enhancement on preoperative dynamic MR images. After
surgery, criteria for differentiation of the normal gland from
the residual enhancing lesion were established by analyzing the
preoperative location and degree of enhancement on dynamic2MR imaging. In postoperative MR images, we analyzed patterns
of residual enhancing lesions and divided them into 2 groups:
peripheral enhancement and nodular enhancement. For each
group, we measured the maximum thickness of the residual
enhancing portion excluding the normal gland, whose location
was delineated on dynamic contrast-enhanced images from both
preoperative and postoperative MRI (Fig. 1). If the peripheral
enhancement had a submillimeter thickness, we regarded it as a 1-
mm thickness. We compared differences between residual tumor
and postoperative changes. Peripheral enhancement was deﬁned
as rim-like contrast enhancement in the periphery of the tumor
bed with uniform thickness. Nodular enhancement was deﬁned
as a focal, nodular, enhancing lesion in the tumor bed with
peripheral enhancement less than 1 mm thick or without
peripheral enhancement. We deﬁned residual tumors as lesions
surgically conﬁrmed by reoperation or residual enhancing lesions
that were observed to be stable or growing upon follow-up MRI.
Evaluation of residual lesions in the cavernous sinus was
excluded from the postoperative MRI analysis. When observers
were in disagreement, they discussed the ﬁndings until they
reached a consensus.
2.4. Statistical analysis
Logistic regressionanalysiswasapplied to identify the related factors
in distinguishing residual tumors from postoperative changes. The
sensitivity, speciﬁcity, accuracy, and the area under the curve were
used todeterminediagnostic accuracyof the thickness of the residual
enhancing lesion for differentiation between postoperative change
and residual tumor. Statistical signiﬁcancewas accepted forP-values
<.05 and the statistical analysis was performed using R software
(http://www.r-project.org).3. Results
There were 52 patients with pituitary macroadenoma who
underwent preoperative, immediate postoperative, and follow-up
sellaMRI. Themean age of patients was 52.8 years (range, 15–75
years) and the study population was composed of 24 men and 28
women. Among the patients, 43 had nonfunctioning pituitary
adenomas and 9 had functioning adenomas. Of the 9 functioning
adenoma patients, 8 had growth hormone-secreting adenomas
and 1 had a thyroid stimulating hormone-secreting adenoma.
The mean size of preoperative pituitary masses was 23.5mm
(range, 9.9–50.1).
A residual tumor was conﬁrmed in 19 patients; mean thickness
was 7.1mm (range, 2.9–16.8). Postoperative changes were
conﬁrmed in 33 patients; mean thickness was 1.9mm (range,
1.0–7.4). Box plots were created for each group with or without
residual tumor (Fig. 2).
The 19 patients with residual tumor were conﬁrmed by a
second operation in 2 patients and by follow-up MRI in 17
patients. Of these 19 patients, 14 showed increased lesion size
upon follow-upMRI. The average interval between the operation
and follow-up MRI at the time of increased lesion size was 7.3
months (range, 2.6–16.4). In the remaining 5 patients, the
residual enhancing pituitary mass was unchanged upon follow-
upMRI with an average follow-up period of 19.2 months (range,
14.4 –27.5). Patterns of residual enhancing lesions in postopera-
tive MRI are shown in Table 1. Of 19 patients with conﬁrmed
residual tumors, most (74%) showed nodular enhancement (n=
16); peripheral enhancement (n=3) was also seen.
Figure 2. Thickness of residual enhancing lesions. The distributions of residual
enhancing lesion thickness in the 2 groups. Thickness of postoperative changes
and residual tumors were signiﬁcantly different (P< .05). Horizontal line, median;
ends of the boxes, upper and lower quartiles; vertical lines, full range of values.
Figure 1. Normal gland on preoperative and postoperative dynamic contrast-enhanced MR images of 2 residual enhancement patterns. Peripheral enhancement
pattern (a, b) and nodular enhancement pattern (c, d). On preoperative MRI (a, c), the location of the normal gland (solid arrows) was demonstrated against the
pituitary adenoma. Upon immediate postoperative MRI (b, d), the normal gland (solid arrows) and residual enhancing lesion (open arrows) were delineated.MRI =
magnetic resonance imaging.
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3Of the total 52 patients, 33 showed peripheral enhancement
with a mean thickness of 1.8mm (range, 1.0–6.2). The mean
thickness of peripheral enhancement without a residual tumor
was 1.6mm (range, 1.0–3.8), and the mean thickness of the
residual tumor (Fig. 3) was 4.6mm (range, 2.9–6.2). Nodular
enhancement with a mean thickness of 7.1mm was seen in 19
patients (range, 3.1–16.8). The mean thickness of nodular
enhancement in residual tumors was 7.5mm (range, 4.0–16.8),Table 1
Enhancement pattern and thickness of early postoperative
pituitary mass.
Enhancement
pattern
Patients with
residual tumor
Patients with
postoperative change
Total
Peripheral 3 (4.6mm,
2.9–6.2)
30 (1.6mm, 1.0–3.8) 33 (1.8mm,
1.0–6.2)
Nodular 16 (7.5mm,
4.0–16.8)
3 (4.7mm, 3.1–7.4) 19 (7.1mm,
3.1–16.8)
Total 19 (7.1mm,
2.9–16.8)
33 (1.9mm, 1.0–7.4)
Parentheses are the mean thickness and range with millimeter measure.
Figure 3. Peripheral enhancement pattern. A 44-yr-old woman with histologically conﬁrmed pituitary adenoma. Dynamic contrast-enhanced coronal images
obtained within 48h after surgery showed (a) a residual enhancing lesion with a peripheral pattern (arrow) in the postoperative tumor bed. Dynamic-enhanced
coronal images obtained 5 mo later (b) revealed involution of the enhancing lesion. A 71-yr-old man with histologically conﬁrmed pituitary adenoma. Dynamic
contrast-enhanced coronal images obtained 48h after surgery showed (c) a residual enhancing lesion with a peripheral pattern (arrow) in the postoperative tumor
bed. Dynamic-enhanced coronal images obtained 11 mo later (d) revealed persistent enhancing lesion, indicating residual tumor.
Kim et al. Medicine (2019) 98:27 Medicineand the mean thickness of nodular enhancement with no residual
tumor (Fig. 4) was 4.7mm (range, 3.1–7.4).
Receiver operating characteristic analysis for the thickness of
residual enhancing lesions in postoperative changes versus
residual tumors is shown in Figure 5. By analyzing threshold
values, we observed that a thickness of 3.9mm was associated
with a sensitivity of 89%, speciﬁcity of 97%, and accuracy of
94% for residual tumor diagnosis.
4. Discussion
Pituitary adenomas are common lesions, accounting for
approximately 10% to 15% of all primary intracranial neo-
plasms and between one-third and one-half of all sellar/
juxtasellar masses.[8] Transsphenoidal microsurgery is the most
common procedure for pituitary adenoma because of its safety
and effectiveness.[9] According to Ciric et al,[10] the rate of
recurrence after this operation is about 12%. Invasive pituitary
adenoma is common and complete surgical removal is not
possible in all cases. Macroadenomas with suprasellar extension
and a height greater than 2.5cm can be difﬁcult to remove
completely using transsphenoidal microsurgery.[6] In hormonally4active pituitary adenomas, persistent or recurrent hypersecretion
of hormones indicates residual or recurrent tumors requiring
follow-up examination. Follow-up imaging might be necessary
for nonfunctioning adenomas or suspected residual tumors at
surgery. Several studies have reported on postoperative changes
of the sella after transsphenoidal resection of a pituitary
adenoma.[1–3,5] These studies did not emphasize detectability
of a tumor upon follow-up MRI because it is difﬁcult to
differentiate a residual tumor from normal glands, implanted
material, or postsurgical granulation tissue on follow-up MR
images performed more than 6 months after surgery. Dina et al[2]
mentioned residual tumors on early postoperative MR images
but the study had few cases with residual tumors. Rodriguez
et al[3] also reported early postoperative changes of the sella but
did not address residual tumors. Yoon et al[7] reported early
postoperative MRI and residual tumor in a relatively large
population of patients who underwent early postoperative MRI
within 7 days after surgery and follow-up MRI every 6 months
thereafter. None of the patients with peripheral rim enhancement
had a residual tumor; the study regarded peripheral rim
enhancement as a compressed normal pituitary gland or
pseudocapsule around the tumor. In that study, follow-up
Figure 4. Nodular enhancement pattern. A 73-yr-old man with histologically conﬁrmed pituitary adenoma. Dynamic contrast-enhanced coronal images obtained
within 48h after surgery showed (a) a residual enhancing lesion with a nodular pattern (arrow) in the postoperative tumor bed. Dynamic-enhanced coronal images
obtained 16 mo later (b) revealed involution of the enhancing lesion. A 68-yr-old woman with histologically conﬁrmed pituitary adenoma. Dynamic contrast-
enhanced coronal images obtained within 48h after surgery showed (c) a residual enhancing lesion with a nodular pattern (arrow) in the postoperative tumor bed.
Dynamic-enhanced coronal images obtained 15 mo later (d) revealed a growing enhancing lesion, indicating residual tumor.
Kim et al. Medicine (2019) 98:27 www.md-journal.comimages showed that peripheral rim enhancement had disappeared
and the normal gland had expanded in the pituitary fossa. The
authors proposed that the nodular portion of an early
postoperative pituitary mass was a residual tumor because the
normal gland did not fully reexpand in the early period after
surgery and the nodular portion showed the same signal intensity
and contrast enhancement as the preoperative adenoma.
Although Yoon et al[7] considered postoperative changes and
residual tumors in early postoperative MRI, they did not show a
quantitative standard for differentiating these occurrences. Our
study divided patients into 2 categories based on the contrast
enhancement pattern of the postoperative tumor bed and the
measured thickness of the residual enhancing portion in each
group. Several reports have suggested that peripheral enhance-
ment on MR images in the postoperative period is a compressed
normal pituitary gland.[1,2,7] In our study, most patients with
peripheral enhancement patterns (91%) showed involution on
follow-up MRI. However, 3 patients had a peripheral enhance-
ment pattern that was stable or increasing upon follow-up MRI.
Normal pituitary glands showed different degrees of enhance-
ment compared to tumors and remaining enhancing portions on
dynamic contrast-enhanced images on both preoperative and5postoperative MR imaging; thus, displaced normal glands can be
delineated and discriminated from tumors and postoperative
residual enhancing lesions. Contrary to a previous report,[7] in
our study, 3 patients with nodular enhancement patterns showed
involution of 3.1mm, 3.5mm, and 7.4mm upon follow-up MRI.
In our study, analysis of the thickness of overall residual
enhancing lesions showed that a thickness greater than 3.9mm is
associated with 89% sensitivity, 97% speciﬁcity, and 94%
accuracy in evaluating residual tumor on early postoperative MR
images. Our results indicate that residual enhancing lesions that
show involution on follow-up MRI may be extremely com-
pressed normal pituitary glands, pseudocapsule swelling, or
residual tumors that have experienced devascularization or
mechanical trauma during surgery. However, it is difﬁcult to
precisely determine if residual enhancing lesions become
involuted upon follow-up MRI. Recent studies[11–14] have
indicated that diffusion-weighted imaging (DWI) can also predict
the consistency of tumors within the sellar region, which has
allowed neurologists to select an appropriate operation plan
before surgery. Ma et al[15] suggested that the cerebral blood
volume value can provide helpful information for assessing the
blood supply of pituitary macroadenoma. Whether DWI and
Figure 5. ROC curves for sensitivity, speciﬁcity, and accuracy of residual
tumor diagnosis. By analyzing threshold values, 3.9-mm thickness was
associated with 89% sensitivity, 97% speciﬁcity, and 94% accuracy for
evaluating residual tumor on early postoperative MRI. MRI = magnetic
resonance imaging, ROC = receiver operating characteristic.
Kim et al. Medicine (2019) 98:27 Medicineperfusion-weighted imaging (PWI) can be used in assessment
after transsphenoidal resection of pituitary adenoma is not yet
clear. Therefore, further studies using an advanced imaging
protocol, such as DWI and PWI, are needed to differentiate
postoperative changes and residual tumors after transsphenoidal
resection of a pituitary adenoma.
This study was limited by its single-center retrospective nature
and the small number of patients. Nonetheless, the reported
imaging ﬁndings of immediate postoperative tumor beds
represent a ﬁrst step toward early diagnosis and the appropriate
treatment of residual tumors. A prospective study with a large
number of patients is needed to establish a more accurate
standard and determine its impact on outcomes.
Upon immediate postoperative MRI after transsphenoidal
resection of pituitary adenoma, residual enhancing lesions with a
thickness greater than 3.9mm and a nodular pattern suggested a
residual tumor. Peripheral enhancements with a thickness less
than 3.9mm tended to improve, according to follow-up MRI,
suggesting postoperative changes rather than a residual tumor.Author contributions
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